Curated summary · agent-written · kb/genes/curated/hgnc_9588.md
All 25 claims checked against the KB draft

PTEN across dismech

PTEN (phosphatase and tensin homolog) is named by 21 disorder entries.

Normal function

ai-gene-review gives PTEN's core molecular functions as phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activity; phosphatidylinositol-3,4-bisphosphate 3-phosphatase activity; and protein serine/threonine phosphatase activity, acting in negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; phosphatidylinositol dephosphorylation; and protein dephosphorylation.

Causative records

Two entries type PTEN as causative: Bannayan-Riley-Ruvalcaba Syndrome; and Familial Nonmedullary Thyroid Carcinoma, and both record the variants as germline (Bannayan-Riley-Ruvalcaba Syndrome; and Familial Nonmedullary Thyroid Carcinoma). In Bannayan-Riley-Ruvalcaba Syndrome the gene sits on the node Germline PTEN Loss of Function.

The two entries most closely identified with the gene record it differently. Cowden Syndrome's genetic record is untyped, as is PTEN Hamartoma Tumor Syndrome's (untyped): both say "Causative" only in the free-text association field, and neither records a variant origin (unrecorded). ClinGen rates PTEN definitive for PTEN hamartoma tumor syndrome, so that entry's record could be typed causative without any new evidence. Cowden Syndrome nonetheless places PTEN on 6 pathophysiology nodes, including PTEN Loss and PI3K/AKT/mTOR Pathway Activation and PTEN Genome Integrity Defect. Nodes naming PTEN in these syndromes conform to the module germline_two_hit_tumor_predisposition.

Somatic driver and untyped records

Three entries type PTEN as a somatic driver: Chromophobe Renal Cell Carcinoma; Endometriosis; and Thyroid Follicular Carcinoma. Two of them record the variant origin as somatic (Chromophobe Renal Cell Carcinoma; and Endometriosis); Thyroid Follicular Carcinoma's is unrecorded. Several carcinoma entries carry PTEN with no relationship type, among them Endometrial Carcinoma; Prostate Adenocarcinoma; and Glioblastoma, IDH-Wildtype; for example Endometrial Carcinoma is untyped.

Where the layers disagree

ClinGen classifies PTEN for 1 disease, and the dismech entries matched to it that do not type the gene are PTEN Hamartoma Tumor Syndrome.

Of the disorders that name PTEN, 14 have a genetic record for it with no relationship_type. That is the main curation gap this page exposes.

The KB's PTEN nodes are annotated with the PI3K/AKT process itself, while ai-gene-review annotates PTEN with the negative regulation of that process, so the two share 0 GO terms by exact identifier. Reading the KB annotation as "PTEN loss increases PI3K/AKT signalling" and the ai-gene-review one as "PTEN normally restrains it" reconciles them; a closure-aware comparison would need the GO hierarchy.

Underlined values are claims re-computed from the knowledge base each time this page is built. The tables below are the source of truth.

Normal function · from ai-gene-review (P60484, commit 79fe13b38970) · AI-generated, not KB evidence

PTEN (Phosphatase and Tensin Homolog) is a critical tumor suppressor encoding a dual-specificity phosphatase with both lipid and protein phosphatase activities. Its primary and essential tumor suppressor function is as a phosphatidylinositol-3,4,5-trisphosphate (PIP3) 3-phosphatase that dephosphorylates PIP3 to PIP2, thereby antagonizing PI3K/AKT/mTOR signaling. PTEN also exhibits protein phosphatase activity against serine, threonine, and tyrosine residues, though the lipid phosphatase activity is the critical determinant of tumor suppression. Nuclear PTEN contributes to genomic stability and cell cycle control. PTEN localizes to the plasma membrane, cytosol, and nucleus, with membrane localization mediated by its C2 domain and PDZ-binding motif interactions with scaffold proteins like MAGI-2. Germline mutations cause PTEN Hamartoma Tumor Syndrome (PHTS/Cowden disease), while somatic mutations occur frequently across many cancer types.

dephosphorylating PIP3 to PIP2 at the plasma membrane to antagonize PI3K/AKT signaling
dephosphorylating PIP2 to PIP at the plasma membrane
dephosphorylating protein substrates at serine and threonine residues
molecular function: protein serine/threonine phosphatase activity · directly involved in: protein dephosphorylation · locations: nucleus; cytosol
In the knowledge base · computed from kb/ at build time

Disorders

Relationship is the entry's genetic[].relationship_type. untyped means the entry has a genetic record for the gene but does not type it; its free-text association is shown instead.

DisorderRelationshipWhere the gene appears
Bannayan-Riley-Ruvalcaba Syndrome causative germline
mechanism: Germline PTEN Loss of Function
variant: PTEN p.Arg130Ter; PTEN p.Arg233Ter; PTEN p.Arg335Ter
Chromophobe Renal Cell Carcinoma somatic driver somatic
Endometriosis somatic driver somatic
Familial Nonmedullary Thyroid Carcinoma causative germline
Thyroid Follicular Carcinoma somatic driver
mechanism: MAPK and PI3K-AKT Pathway Activation
BRAF V600E-Mutant Colorectal Cancer untyped
Co-occurring Loss of Function
Chordoma untyped
Somatic Pathway Activation
Cowden Syndrome untyped
Causative
mechanism: Hamartoma Formation; Increased Cancer Risk; Neurodevelopmental Cortical Dysfunction; PTEN Genome Integrity Defect; PTEN Loss and PI3K/AKT/mTOR Pathway Activation; Reduced Succinate Dehydrogenase Activity
subtype: CS1
animal model: Epithelial-specific Pten deletion (colorectal juvenile polyposis); Mammary Pten loss with constitutive Stat5 activation; Neuronal Pten deletion (macrocephaly and social-behaviour phenotypes)
scoped to subtype: CS1
Cutaneous Melanoma untyped
Somatic loss of function
Endometrial Carcinoma untyped
Somatic loss-of-function mutation
mechanism: PTEN PI3K Pathway Dysregulation
Endometrial Endometrioid Adenocarcinoma untyped
Recurrent somatic driver alteration
somatic
mechanism: PTEN PI3K Pathway Dysregulation
Gastroenteropancreatic Neuroendocrine Neoplasm untyped
Inactivating mutations in ~7% of pancreatic NETs; mTOR pathway component
Glioblastoma, IDH-Wildtype untyped
Loss/Mutation
Juvenile Polyposis Syndrome untyped
Subtype-specific contiguous deletion partner
Melanoma_in_Congenital_Melanocytic_Nevus untyped
Loss of function
mechanism: PI3K-AKT-mTOR Pathway Activation
Ovarian Endometrioid Carcinoma untyped
Loss-of-function mutation
mechanism: PI3K-AKT Pathway Activation
Pancreatic Neuroendocrine Tumor untyped
Inactivating mutations in ~7% of pNETs; mTOR pathway component
Prostate Adenocarcinoma untyped
Somatic loss or deletion
PTEN Hamartoma Tumor Syndrome untyped
Causative
mechanism: PTEN loss and PI3K AKT mTOR activation
BRAF V600 Mutant Melanoma no genetic record
mechanism: PTEN-Loss and PI3K-AKT-mTOR Cooperation
animal model: Mus musculus
Neurofibromatosis Type 1 no genetic record
mechanism: Malignant Peripheral Nerve Sheath Tumor Progression
ClinGen gene–disease validity · snapshot 2026-10-03 · matched to entries by MONDO

An entry matches when ClinGen's MONDO disease is the entry's own disease term, a subtype term, or an exact-match mapping. An amber status marks an entry ClinGen supports the gene for (Definitive, Strong or Moderate) whose own record does not type it. A Limited, Disputed or Refuted tier on such an entry is not a gap.

ClinGen diseaseMOIClassificationdismech entry
PTEN hamartoma tumor syndrome MONDO:0017623 AD Definitive
2024-04-05
Mechanism modules · computed from kb/

Identity from HGNC (snapshot 2026-10-01). Page layers are described in the gene pages documentation.